Abstract
Candida albicans, a major fungal pathogen, poses significant challenges due to antifungal resistance, particularly in immunocompromised individuals. Natural compounds, such as 6-gingerol, derived from Zingiber officinale (ginger), have gained attention for their therapeutic potential. This study investigates the antifungal activity of 6-gingerol against C. albicans using in silico approaches, including molecular docking, ADMET profiling, and interaction analysis. Molecular docking results demonstrated that 6-gingerol exhibits potential inhibitory interactions with key fungal targets N-myristoyltransferase and Sterol 14-alpha demethylase, facilitated by hydrogen bonding and hydrophobic forces. ADMET analysis revealed favorable pharmacokinetic and safety profiles, including low toxicity, supporting its potential as a natural antifungal agent. These findings suggest that 6-gingerol, a bioactive compound from ginger, holds promise for further exploration in antifungal drug development. Experimental assessment using in vitro and in vivo experiments is advised to verify its effectiveness and suitability for clinical applications.